Search

Your search keyword '"Molenaar, Jan"' showing total 879 results

Search Constraints

Start Over You searched for: Author "Molenaar, Jan" Remove constraint Author: "Molenaar, Jan"
879 results on '"Molenaar, Jan"'

Search Results

1. An assessment of overall effectiveness of agricultural multi-stakeholder initiatives with specific attention to smallholder inclusiveness, and recommendations for improvement

2. Fair Company–Community Partnerships in Palm Oil Development

3. A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery

8. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

12. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

13. Putting food systems thinking into practice: Integrating agricultural sectors into a multi-level analytical framework

14. Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma

15. Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function

17. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

18. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

22. Multi-dimensional profiling of hepatoblastomas and patient-derived tumor organoids uncovers tumor subpopulations with divergent WNT activation profiles and identifies pan-hepatoblastoma drug sensitivities

23. Two opposing gene expression patterns within ATRX aberrant neuroblastoma

24. P316: PRIORITIZING PRECISION MEDICINES IN PEDIATRIC BLOOD CANCER: EXPERIENCE OF THE DUTCH INDIVIDUALIZED THERAPY (ITHER) STUDY’S MOLECULAR TUMOR BOARD

26. ALK positively regulates MYCN activity through repression of HBP1 expression

28. Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’

29. Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM

30. Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents

31. From class waivers to precision medicine in paediatric oncology

33. Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma

35. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity

36. Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors

37. Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models

38. Abstract 234: ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput in vivo testing

39. Supplementary Table from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

40. Supplementary Materials and Methods from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

41. Data from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

42. Supplementary Data from International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer

43. Supplementary Data from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

44. Data from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

45. Supplementary Figure from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

46. Supplementary Figure 1 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy

47. Supplementary Figure 7 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy

48. Supplementary Figure 6 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy

49. Supplementary Figure 8 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy

50. Supplementary Materials and Methods from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma

Catalog

Books, media, physical & digital resources